Atlas Venture Fund X Amends Tectonic Therapeutic Stake

TL;DR

Atlas Venture Fund X just updated their Tectonic Therapeutic stake. Big VC player involved.

AI Summary

Atlas Venture Fund X, L.P. has amended its Schedule 13D filing regarding Tectonic Therapeutic, Inc. on October 28, 2024. The filing indicates a change in beneficial ownership, with Atlas Venture Fund X, L.P. now holding a significant stake in the company. The filing also lists other related Atlas Venture entities as group members.

Why It Matters

This filing signals a potential shift in control or influence for Tectonic Therapeutic, as a major venture capital firm adjusts its holdings. Investors will monitor future actions by Atlas Venture.

Risk Assessment

Risk Level: medium — Changes in beneficial ownership by significant investors like venture capital firms can indicate strategic shifts or potential future actions that may impact the company's stock price.

Key Players & Entities

• Atlas Venture Fund X, L.P. (company) — Filing entity and significant shareholder
• Tectonic Therapeutic, Inc. (company) — Subject company
• Atlas Venture Associates Opportunity I, L.P. (company) — Group member
• Atlas Venture Associates Opportunity I, LLC (company) — Group member
• Atlas Venture Associates X, L.P. (company) — Group member
• Atlas Venture Associates X, LLC (company) — Group member
• Atlas Venture Opportunity Fund I, L.P. (company) — Group member

FAQ

Key Financial Figures

• $0.0001 — Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class o
• $33.59 — ted transaction with a single buyer for $33.59 per share. (d) No other person is k

Filing Documents

• tm2426988d1_sc13da.htm (SC 13D/A) — 117KB
• 0001104659-24-111899.txt ( ) — 119KB

(b) of the Initial Schedule 13D is hereby

Item 2(b) of the Initial Schedule 13D is hereby amended and restated as follows: (b) The address of the principal place of business of each of the Reporting Persons is c/o 300 Technology Square, 8th Floor, Cambridge, Massachusetts 02139. ITEM 4. PURPOSE OF TRANSACTION

of the Initial Schedule 13D is hereby amended

Item 4 of the Initial Schedule 13D is hereby amended and supplemented as follows: Effective upon the completion of the Reverse Merger, Bruce Booth, D.Phil., resigned as a director of the Issuer. CUSIP 878972108 Page 9 of 10 ITEM 5. INTEREST IN SECURITIES OF THE ISSUER

of the Initial Schedule 13D is hereby amended

Item 5 of the Initial Schedule 13D is hereby amended and restated as follows: (a) (b) As of the date hereof, Atlas X is the record owner of 9,171 shares of Common Stock. AVA X LP is the general partner of Atlas X and AVA X LLC is the general partner of AVA X LP. Each of Atlas X, AVA X LP and AVA X LLC has shared voting and dispositive power over the shares held by Atlas X. As such, each of Atlas X, AVA X LP and AVA X LLC may be deemed to beneficially own the shares held by Atlas X. As of the date hereof, AVA X LP is the record owner of 1,709 shares of Common Stock. AVA X LLC is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC has shared voting and dispositive power over the shares held by AVA X LP. As such, each of AVA X LP and AVA X LLC may be deemed to beneficially own the shares held by AVA X LP. As of the date hereof, AVOF is the record AVOF, AVAO LP and AVAO LLC has shared voting and dispositive power over the shares held by AVOF. As such, each of AVOF, AVAO LP and AVAO LLC may be deemed to beneficially own the shares held by AVOF. Each of the Fund X Reporting Persons and Opportunity Fund Reporting Persons may be deemed to beneficially own 0.1% and 0.5%, respectively, of the Issuer’s outstanding Common Stock, which percentages are calculated based upon 14,734,479 outstanding shares of Common Stock, as reported in the Issuer's prospectus supplement filed with the Securities and Exchange Commission on August 14, 2024. Collectively, the Reporting Persons beneficially own an aggregate of 78,447 shares of Common Stock, which represents 0.5% of the Issuer's outstanding Common Stock. The Fund X Reporting Persons and the Opportunity Fund Reporting Persons are under common control and as a result, the Reporting Persons may be deemed to be members of a group. However, the Reporting Persons disclaim such group m

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: October 28, 2024 ATLAS VENTURE FUND X, L.P. By: Atlas Venture Associates X, L.P., its general partner By: Atlas Venture Associates X, LLC, its general partner By: /s/ Ommer Chohan Name: Ommer Chohan Title: Chief Financial Officer ATLAS VENTURE ASSOCIATES X, L.P. By: Atlas Venture Associates X, LLC, its general partner By: /s/ Ommer Chohan Name: Ommer Chohan Title: Chief Financial Officer ATLAS VENTURE ASSOCIATES X, LLC By: /s/ Ommer Chohan Name: Ommer Chohan Title: Chief Financial Officer ATLAS VENTURE OPPORTUNITY FUND I, L.P. By: Atlas Venture Associates Opportunity I, L.P., its general partner By: Atlas Venture Associates Opportunity I, LLC, its general partner By: /s/ Ommer Chohan Name: Ommer Chohan Title: Chief Financial Officer ATLAS VENTURE ASSOCIATES OPPORTUNITY I, L.P. By: Atlas Venture Associates Opportunity I, LLC, its general partner By: /s/ Ommer Chohan Name: Ommer Chohan Title: Chief Financial Officer ATLAS VENTURE ASSOCIATES OPPORTUNITY I, LLC By: /s/ Ommer Chohan Name: Ommer Chohan Title: Chief Financial Officer

View Full Filing

View this SC 13D/A filing on SEC EDGAR